•   
  •   
  •   

Politics The first tests for a coronavirus vaccine are very encouraging

23:25  18 may  2020
23:25  18 may  2020 Source:   pressfrom.com

Trump says coronavirus will disappear without a vaccine. Fauci has said the opposite.

  Trump says coronavirus will disappear without a vaccine. Fauci has said the opposite. "This is going to go away without a vaccine," Trump said Friday, citing doctors. Anthony Fauci, though, has offered a very different take.But on Friday, Trump seemed to shift his rhetoric on the topic, saying that we don’t even need one for the virus to go away. “I just rely on what doctors say,” Trump said when pressed.

Les premiers tests d’un vaccin contre le coronavirus sont très encourageants © SOPA Images / Contributor / Getty Images The first tests for a coronavirus vaccine are very encouraging The American laboratory Moderna announced on Monday May 18 " positive interim data "from the initial phase of clinical trials for its coronavirus vaccine project.

This is an announcement that will spark hope around the world. The American biotechnology company Moderna, one of the most advanced in the race to find an vaccine against the new coronavirus , announced on Monday May 18 very preliminary, but encouraging results for its experimental vaccine in eight volunteers, before tests large-scale planned for July. The young company, in which the US government has invested $ 483 million, has announced "positive interim data" from the initial phase of clinical trials.77

Federal Government approves 750 million euro program for coronavirus vaccine

 Federal Government approves 750 million euro program for coronavirus vaccine © Bernd von Jutrczenka Anja Karliczek (CDU), Federal Minister of Education and Research. Berlin. The federal government plans to provide up to 750 million euros for the development of a vaccine. However, Federal Research Minister Anja Karliczek (CDU) does not expect its operational capability until mid-2021 - and thus a return to normal. The Federal Government is providing up to 750 million euros for the development and production of a corona vaccine.

Indeed, in eight people, the vaccine project called mRNA- 1273 elicited an immune response similar to that seen in people who have been naturally infected with the virus that causes Covid-19. This first phase also aimed to verify that the vaccine is not toxic, and Moderna only reported a few side effects such as redness at the injection site. The American laboratory was one of the first two to inject humans with its vaccine project on March 16. To date, only 12 clinical trials have started with human volunteers worldwide, half of them in China, according to the London School of Hygiene & Tropical Medicine, on a hundred projects identified.

>> Read also - Covid-19 vaccine: the Pasteur Institute aims for first results in October

Trump czar aiming for as many as 50 million coronavirus tests a month by September

  Trump czar aiming for as many as 50 million coronavirus tests a month by September Adm. Brett Giroir, who is overseeing the Trump administration's coronavirus testing efforts, said on Tuesday that he hopes the U.S. will be testing tens of millions of people a month by the fall."So by September, taking every aspect of development, authorization, manufacturing and supply chain into consideration, we project that our nation will be capable of performing at least 40 [million] to 50 million tests per month if needed at that time," Giroir said during a virtual hearing before a Senate panel. require(["medianetNativeAdOnArticle"], function (medianetNativeAdOnArticle) { medianetNativeAdOnArticle.

The administration of President Donald Trump , who wants 300 million doses by January to vaccinate the American population , invested early in the Moderna project as well as in the less advanced ones of the American group Johnson & Johnson and the French laboratory Sanofi, which has production sites in the United States. It is still far too early to predict the future of this vaccine, based on a technology called messenger RNA, which has never proven to be effective.

The technology aims to give the body the genetic information it needs to preventively protect against coronavirus. The full results of the phase 1 trial, on 45 participants aged 18 to 55, are not yet known. "This is not bad news," tempers in an understatement Stephen Evans, professor at the London School of Hygiene & Tropical Medicine. He notes that these first figures relate to relatively young patients only, while Covid-19 is more dangerous in those over 70 years of age.

Trump to tap ex-Glaxo exec, U.S. general for coronavirus vaccine effort

  Trump to tap ex-Glaxo exec, U.S. general for coronavirus vaccine effort Trump to tap ex-Glaxo exec, U.S. general for coronavirus vaccine effortThe former head of Glaxo's vaccines division, Moncef Slaoui, will serve as chief adviser on the operation and U.S. General Gustav Perna will act as its chief operating officer. Trump previously said he would be the top boss on the effort to develop, test and produce on a shortened timeline a vaccine against the deadly coronavirus that has caused a global pandemic.

The results of phase 3 will allow us to decide on the effectiveness of

"It is very difficult to be sure of the results from a press release", he adds, stressing that only the results of the future phase 3 will make it possible to decide on efficiency. Phase 2, out of 600 people, has already received the green light from the American Medicines Agency (FDA) and should start by June. Phase 3, with even more participants, is slated to begin in July, said Stephen Hoge, president of Moderna.

The vaccine was developed in partnership with the National Institute of Infectious Diseases (NIAID), led by Doctor Anthony Fauci. The institute is also conducting the clinical trial. The first data "lead us to believe that mRNA-1273 has a high probability of creating protection" against the coronavirus, welcomed in a conference call Stéphane Bancel, the French director general of Moderna. "We are overwhelmed by these interim data," he said.

Moderna share price in New York up 26%

The company founded nine years ago and based in Cambridge near Boston, has so far never received a registration for a drug or a vaccine. In the process, Moderna's New York share price was up 26% at midday.

Spahn will soon begin to significantly expand the coronavirus tests .
© ANGELA WEISS Federal Minister of Health Jens Spahn will soon begin to significantly expand the tests for the coronavirus. In May he wanted to present a regulation that would enable series tests in hospitals and nursing homes, Spahn said. Federal Minister of Health Jens Spahn (CDU) wants to start soon with a significant extension of the tests to the corona virus.

—   Share news in the SOC. Networks
usr: 0
This is interesting!